SOURCE: Genomind

SOURCE: FirstLab

April 25, 2014 09:00 ET

Genomind and FirstLab Announce Leadership Changes

CHALFONT, PA--(Marketwired - April 25, 2014) - Dr. Ronald I. Dozoretz, Founder and Chairman of Genomind and FirstLab, today announced leadership changes to both companies. Michael Koffler has been appointed by the Board of Directors to lead Genomind as President and Chief Executive Officer. He will succeed Scott A. Storrer who served as President and Chief Executive Officer of Genomind for three years and will now lead FirstLab full time as President and Chief Executive Officer.

Genomind is a personalized medicine company whose saliva-based genetic test is used to help inform treatment response for patients with psychiatric disorders. Mr. Koffler has served as the company's Chief Financial Officer for the past three years and helped lead the company from its commercial launch through its recent capital raise and expansion. 

FirstLab, the leading International Third Party Administrator of drug and alcohol testing and employer service programs, has successfully completed a business turn-around where Mr. Storrer led the team through investing in sales, distribution, customer service and technology, which made FirstLab the industry leading company that it is today. 

"This is a natural transition for FirstLab and Genomind's next phase of growth and Scott and Michael have been instrumental in the success of both companies," said Dr. Dozoretz. "I am delighted that both businesses will be in the hands of experienced leaders who truly understand their customers' needs and expectations."

"I am pleased with the strong growth that FirstLab is experiencing," said Mr. Storrer. "I look forward to devoting my full attention to the exciting challenges that lie ahead for the team and the business."

"Genomind is at the forefront of bringing personalized medicine to neuropsychiatry, and I am excited and honored to lead such a talented team as we pursue our mission of improving the lives of patients," said Mr. Koffler. "Our goal is to help make our current innovative test, the Genecept™ Assay, more widely available to patients so they can receive the most appropriate interventions sooner in their treatment process."

About Genomind

Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients' lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at

About FirstLab

Founded in 1989, FirstLab is now the largest, private Third party Administrator of drug and alcohol testing programs in the country. We are known for our regulatory, legal and technical expertise in substance abuse testing, policies and procedures. We believe our success is a testament to our legacy of progressive results-driven thinking. Our executive team is comprised of leading experts in regulatory compliance and scientific innovation. They are also champions of customer service, ensuring that our clients have comprehensive, up-to-the minute information on the latest changes to policies, procedures and best practices. FirstLab's distinguished medical team leads the healthcare industry with ongoing thought leadership and innovation. Learn more at

Contact Information

  • For more information, contact:

    Doreen Korba
    Vice President, Marketing and Corporate Communications